Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press24910.17650/2220-3478-2018-8-2-38-45ORIGINAL REPORTSОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯEfficacy of continuing anti-angiogenic agents in the second-line treatment for metastatic colon cancer depending on the KRAS mutation status: a meta-analysisМетаанализ исследований по оценке эффективности продолжения применения антиангиогенных препаратов во 2-й линии терапии больных метастатическим раком толстой кишки в зависимости от мутационного статуса гена KRAShttps://orcid.org/0000-0001-5615-7806FedyaninM. Yu.ФедянинМ. Ю.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

Михаил Юрьевич Федянин

115478 Москва, Каширское шоссе, 24

fedianinmu@mail.ruhttps://orcid.org/0000-0003-2245-214XTryakinA. A.ТрякинА. А.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

https://orcid.org/0000-0001-9807-2229TjulandinS. A.ТюляндинС. А.
Russian Federation

115478 Москва, Каширское шоссе, 24

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России24 Kashirskoe Shosse, Moscow 115478ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России120720188238451207201812072018Copyright ©; 2018, Fedyanin M.Y., Tryakin A.A., Tjulandin S.A.Copyright ©; 2018, Федянин М.Ю., Трякин А.А., Тюляндин С.А.2018Fedyanin M.Y., Tryakin A.A., Tjulandin S.A.Федянин М.Ю., Трякин А.А., Тюляндин С.А.https://creativecommons.org/licenses/by/4.0https://onco-surgery.info/jour/article/view/249

colon canceranti-angiogenic therapychemotherapyrandomized trialsmeta-analysismutation in the KRAS gene: рак толстой кишкиантиангиогенная терапияхимиотерапиярандомизированные исследованияметаанализмутация в гене KRAS1. Bennouna J., Sastre J., Arnold D. et al. ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14(1):29–37. PMID: 23168366. DOI: 10.1016/S14702045(12)70477-1.Bennouna J., Sastre J., Arnold D. et al. ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14(1):29–37. PMID: 23168366. DOI: 10.1016/S14702045(12)70477-1.2. Kubicka S., Greil R., André T. et al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol 2013;24(9):2342–9. PMID: 23852309. DOI: 10.1093/annonc/mdt231.Kubicka S., Greil R., André T. et al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol 2013;24(9):2342–9. PMID: 23852309. DOI: 10.1093/annonc/mdt231.3. Van Cutsem E., Tabernero J., Lakomy R. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatinbased regimen. J Clin Oncol 2012;30:3499–506. PMID: 22949147. DOI: 10.1200/JCO.2012.42.8201.Van Cutsem E., Tabernero J., Lakomy R. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatinbased regimen. J Clin Oncol 2012;30:3499–506. PMID: 22949147. DOI: 10.1200/JCO.2012.42.8201.4. Wirapati P., Pomella V., Vandenbosch B. et al. VELOUR trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity. J Clin Oncol 2017;35(Suppl 15):3538. DOI: 10.1200/JCO.2017.35.15_suppl.3538.Wirapati P., Pomella V., Vandenbosch B. et al. VELOUR trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity. J Clin Oncol 2017;35(Suppl 15):3538. DOI: 10.1200/JCO.2017.35.15_suppl.3538.5. Tabernero J.T., Yoshino T., Cohn A.L. et al. Ramucirumab versus placebo in combination with second line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015;16(5):499–508. PMID: 25877855. DOI: 10.1016/S1470-2045(15)70127-0.Tabernero J.T., Yoshino T., Cohn A.L. et al. Ramucirumab versus placebo in combination with second line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015;16(5):499–508. PMID: 25877855. DOI: 10.1016/S1470-2045(15)70127-0.6. Obermannová R., Van Cutsem E., Yoshino T. et al. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Ann Oncol 2016;27(11):2082– 90. PMID: 27573561. DOI: 10.1093/annonc/mdw402.Obermannová R., Van Cutsem E., Yoshino T. et al. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Ann Oncol 2016;27(11):2082– 90. PMID: 27573561. DOI: 10.1093/annonc/mdw402.7. Hurwitz H.I., Tebbutt N.C., Kabbinavar F. et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 2013;18(9);1004–12. PMID: 23881988. DOI: 10.1634/theoncologist.2013-0107.Hurwitz H.I., Tebbutt N.C., Kabbinavar F. et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 2013;18(9);1004–12. PMID: 23881988. DOI: 10.1634/theoncologist.2013-0107.8. Giantonio B.J., Catalano P.J., Meropol N.J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539–44. PMID: 17442997. DOI: 10.1200/JCO.2006.09.6305.Giantonio B.J., Catalano P.J., Meropol N.J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539–44. PMID: 17442997. DOI: 10.1200/JCO.2006.09.6305.9. Masi G., Salvatore L., Boni L. et al. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol 2015;26(4):724–30. PMID: 25600568. DOI: 10.1093/annonc/mdv012.Masi G., Salvatore L., Boni L. et al. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol 2015;26(4):724–30. PMID: 25600568. DOI: 10.1093/annonc/mdv012.10. Tabernero J., Lenz H.J., Siena S. et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 2015;16(8):937–48. PMID: 26184520. DOI: 10.1016/S14702045(15)00138-2.Tabernero J., Lenz H.J., Siena S. et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 2015;16(8):937–48. PMID: 26184520. DOI: 10.1016/S14702045(15)00138-2.